Your browser doesn't support javascript.
loading
Immune checkpoint therapy-current perspectives and future directions.
Sharma, Padmanee; Goswami, Sangeeta; Raychaudhuri, Deblina; Siddiqui, Bilal A; Singh, Pratishtha; Nagarajan, Ashwat; Liu, Jielin; Subudhi, Sumit K; Poon, Candice; Gant, Kristal L; Herbrich, Shelley M; Anandhan, Swetha; Islam, Shajedul; Amit, Moran; Anandappa, Gayathri; Allison, James P.
Afiliação
  • Sharma P; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; The Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX
  • Goswami S; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Raychaudhuri D; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Siddiqui BA; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Singh P; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Nagarajan A; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Liu J; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; MD Anderson UT Health Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Subudhi SK; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Poon C; Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Gant KL; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Herbrich SM; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Anandhan S; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; MD Anderson UT Health Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Islam S; Department of Head & Neck Surgery Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Amit M; Department of Head & Neck Surgery Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Anandappa G; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Allison JP; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; The Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Cell ; 186(8): 1652-1669, 2023 04 13.
Article em En | MEDLINE | ID: mdl-37059068
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imunoterapia / Neoplasias Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Cell Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imunoterapia / Neoplasias Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Cell Ano de publicação: 2023 Tipo de documento: Article